Iron Chelation Therapy Updates (Oral Deferasirox)

Pathophysiological Basis and Pharmacological Profile

Chronic packed red blood cell (PRBC) transfusions in hemoglobinopathies lead to massive secondary iron overload, as each unit contains 200-250 mg of elemental iron.
Non-transfusion-dependent thalassemia (NTDT) causes hepcidin suppression and subsequent dietary iron hyperabsorption.
Toxic non-transferrin-bound iron generates massive oxidative stress via the Fenton reaction, leading to restrictive cardiomyopathy, cirrhosis, and endocrinopathies.
Deferasirox (DFX) is a tridentate oral iron chelator that binds ferric iron in a 2:1 ratio.
DFX possesses an 8-16 hour plasma half-life permitting once-daily dosing and relies on hepatobiliary excretion.

Global protocols have completely transitioned from Dispersible Tablets (DT) to Film-Coated Tablets (FCT).

Parameter	Dispersible Tablets (DT - Exjade)	Film-Coated Tablets (FCT - Jadenu/Generics)
Administration	Requires dispersion in liquid on an empty stomach.	Swallowed whole with a light meal.
Tolerability	Unpalatable, gritty, causes severe gastrointestinal distress.	Lacks irritating excipients, vastly improved adherence.
Bioavailability	Baseline reference.	Approximately 30% higher bioavailability.
TDT Dosing	Higher absolute mg/kg dosing required.	Start 14 mg/kg/day, maximum 28 mg/kg/day.
NTDT Dosing	Higher absolute mg/kg dosing required.	Start 7 mg/kg/day, maximum 14 mg/kg/day.

Indian Society of Haematology and Blood Transfusion (ISHBT) 2026 guidelines mandate chelation initiation after 10-20 PRBC transfusions or when serum ferritin consistently exceeds 1000 ng/mL.
The maintenance target is a serum ferritin level of 500-1000 ng/mL.
Ferritin levels below 300 ng/mL drastically increase the risk of DFX-induced renal toxicity due to the stripping of functional iron from metalloenzymes.

Dual Oral Iron Chelation (DOIC): Combines DFX and Deferiprone (DFP) for refractory cases. DFP acts as an intracellular shuttle extracting mitochondrial iron, while DFX acts as a plasma sink. DOIC is now the preferred rescue therapy for iron overload cardiomyopathy.
Amlodipine Adjuvant: This L-type voltage-dependent calcium channel blocker physically prevents toxic iron entry into cardiomyocytes, significantly improving cardiac T2* by an average of 2.79 milliseconds.
Gene Therapy Pre-Conditioning: Maximal DFX therapy is strictly mandated prior to CRISPR/Cas9 gene therapy to reduce hepatic iron and prevent lethal hepatic veno-occlusive disease during busulfan conditioning.

Tissue Iron Quantification: MRI T2* is the gold standard; a cardiac T2* < 10 milliseconds indicates severe myocardial siderosis and a high risk of sudden cardiac death.
Renal Toxicity: DFX can cause reversible creatinine elevation and Fanconi syndrome; baseline creatinine clearance, weekly serum creatinine, and urine protein/creatinine ratios are mandatory initially.
Hepatic Toxicity: Requires transaminase monitoring every two weeks during the first month, then monthly.
Gastrointestinal Toxicity: Severe mucosal ulceration and hemorrhage require immediate drug cessation if suspected.
Sensory Toxicity: Annual audiograms and slit-lamp examinations are standard of care to monitor for high-frequency sensorineural hearing loss and cataracts.# Iron Chelation Therapy Updates

Chronic packed red blood cell (PRBC) transfusions in hemoglobinopathies lead to massive secondary iron overload, as each unit contains 200-250 mg of elemental iron.
Non-transfusion-dependent thalassemia (NTDT) causes hepcidin suppression and subsequent dietary iron hyperabsorption.
Toxic non-transferrin-bound iron generates massive oxidative stress via the Fenton reaction, leading to restrictive cardiomyopathy, cirrhosis, and endocrinopathies.
Deferasirox (DFX) is a tridentate oral iron chelator that binds ferric iron in a 2:1 ratio.
DFX possesses an 8-16 hour plasma half-life permitting once-daily dosing and relies on hepatobiliary excretion.

Global protocols have completely transitioned from Dispersible Tablets (DT) to Film-Coated Tablets (FCT).

Parameter	Dispersible Tablets (DT - Exjade)	Film-Coated Tablets (FCT - Jadenu/Generics)
Administration	Requires dispersion in liquid on an empty stomach.	Swallowed whole with a light meal.
Tolerability	Unpalatable, gritty, causes severe gastrointestinal distress.	Lacks irritating excipients, vastly improved adherence.
Bioavailability	Baseline reference.	Approximately 30% higher bioavailability.
TDT Dosing	Higher absolute mg/kg dosing required.	Start 14 mg/kg/day, maximum 28 mg/kg/day.
NTDT Dosing	Higher absolute mg/kg dosing required.	Start 7 mg/kg/day, maximum 14 mg/kg/day.

Indian Society of Haematology and Blood Transfusion (ISHBT) 2026 guidelines mandate chelation initiation after 10-20 PRBC transfusions or when serum ferritin consistently exceeds 1000 ng/mL.
The maintenance target is a serum ferritin level of 500-1000 ng/mL.
Ferritin levels below 300 ng/mL drastically increase the risk of DFX-induced renal toxicity due to the stripping of functional iron from metalloenzymes.

Dual Oral Iron Chelation (DOIC): Combines DFX and Deferiprone (DFP) for refractory cases. DFP acts as an intracellular shuttle extracting mitochondrial iron, while DFX acts as a plasma sink. DOIC is now the preferred rescue therapy for iron overload cardiomyopathy.
Amlodipine Adjuvant: This L-type voltage-dependent calcium channel blocker physically prevents toxic iron entry into cardiomyocytes, significantly improving cardiac T2* by an average of 2.79 milliseconds.
Gene Therapy Pre-Conditioning: Maximal DFX therapy is strictly mandated prior to CRISPR/Cas9 gene therapy to reduce hepatic iron and prevent lethal hepatic veno-occlusive disease during busulfan conditioning.

Tissue Iron Quantification: MRI T2* is the gold standard; a cardiac T2* < 10 milliseconds indicates severe myocardial siderosis and a high risk of sudden cardiac death.
Renal Toxicity: DFX can cause reversible creatinine elevation and Fanconi syndrome; baseline creatinine clearance, weekly serum creatinine, and urine protein/creatinine ratios are mandatory initially.
Hepatic Toxicity: Requires transaminase monitoring every two weeks during the first month, then monthly.
Gastrointestinal Toxicity: Severe mucosal ulceration and hemorrhage require immediate drug cessation if suspected.
Sensory Toxicity: Annual audiograms and slit-lamp examinations are standard of care to monitor for high-frequency sensorineural hearing loss and cataracts.